Average Co-Inventor Count = 4.20
ph-index = 6
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Bristol-myers Squibb Compnay (24 from 3,684 patents)
2. Sloan-kettering Institute for Cancer Research (3 from 512 patents)
3. Bristol-myers Squibb Pharma Company (1 from 234 patents)
28 patents:
1. 11673886 - 5-membered and bicyclic heterocyclic amides as inhibitors of ROCK
2. 11078197 - 5-membered and bicyclic heterocyclic amides as inhibitors of rock
3. 10829501 - Spiroheptane salicylamides and related compounds as inhibitors of ROCK
4. 10787450 - Spiro-fused cyclic ureas as inhibitors of rock
5. 10730858 - Lactam, cyclic urea and carbamate, and triazolone derivatives as potent and selective rock inhibitors
6. 10696674 - Spirolactams as inhibitors of ROCK
7. 10654860 - Tricyclic rho kinase inhibitors
8. 10611776 - Spiroheptane salicylamides and related compounds as inhibitors of rock
9. 10562887 - Triazolones and tetrazolones as inhibitors of ROCK
10. 10385026 - Phthalazinones and isoquinolinones as rock inhibitors
11. 10123993 - Cyclic ureas as inhibitors of rock
12. 10112929 - Lactams as inhibitors of rock
13. 9926282 - Phthalazinones and isoquinolinones as rock inhibitors
14. 9902702 - Spirocycloheptanes as inhibitors of rock
15. 9458110 - Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors